Acute vs Chronic Graft-Versus-Host Disease: How Timing and Organs Involved Shape Treatment

Six weeks after her brother’s stem cells were infused into her bloodstream, a woman notices a faint pink rash across her shoulders while getting dressed. It looks like mild sunburn. Her transplant coordinator asks her to photograph it and come in that afternoon. Two years later, a different patient in the same waiting room is being fitted for special eye drops because his eyes feel like sandpaper, and the skin over his forearms has grown tight and shiny.

Both of these people have graft-versus-host disease. Yet what is happening inside them, how their doctors will grade it, and how long treatment might run could hardly be more different. That is the heart of the acute vs chronic GVHD question, and it matters far more than the words “acute” and “chronic” suggest.

This explainer walks through what separates the two forms, why the calendar has quietly lost its authority in diagnosis, how organ involvement drives every treatment choice, and where the genuine uncertainties still sit.

What are the two main types of GVHD?

Graft-versus-host disease, usually shortened to GVHD, is a complication of an allogeneic transplant. “Allogeneic” simply means the stem cells come from another person rather than from the patient’s own body. The “graft” is the donor’s immune system arriving in the patient; the “host” is the patient. Disease occurs when donor immune cells recognize the host’s tissues as foreign and attack them (MedlinePlus).

Clinicians divide GVHD into two main types: acute and chronic. Acute GVHD is the early, often fast-moving form that classically shows up in the skin, the digestive tract and the liver. Chronic GVHD is the later, slower form that behaves more like an autoimmune condition and can settle into many organs, including the eyes, mouth, lungs and joints (Cleveland Clinic).

The split is not merely academic. The two forms are graded with different systems, carry different risks, and follow different treatment arcs. A patient with acute gut GVHD may be in hospital receiving intravenous fluids and steroids within days of the first symptom. A patient with chronic GVHD of the skin might be managed largely as an outpatient over several years, with regular checks of lung function and eye health along the way.

There is also an in-between category. The National Institutes of Health consensus criteria describe an “overlap syndrome,” where a patient shows features of both forms at the same time (NIH consensus, PubMed). Recognizing overlap matters because it tells the team that both the acute and the chronic processes are active, which shapes how aggressively and for how long they treat.

Knowing which type you are dealing with is therefore the first real decision point after a diagnosis of GVHD, and it sets the tone for everything that follows.

How GVHD actually happens: donor immune cells meet a new body

Every cell in the body carries surface markers called human leukocyte antigens, or HLA, which act like an identity badge. Donors are matched to recipients as closely as possible on these markers. Even with a well-matched sibling, however, thousands of smaller differences remain, and donor T cells (a type of white blood cell that coordinates immune attacks) can pick up on them (Johns Hopkins Medicine).

Acute GVHD unfolds in roughly three steps. First, the chemotherapy or radiation given before transplant damages tissues, especially the lining of the gut, and releases inflammatory signals. Second, those signals prime donor T cells, which multiply and are drawn toward the skin, liver and intestines. Third, the activated cells and the chemical messengers they release cause direct tissue injury. The result is inflammation that can appear within a few weeks of the transplant.

Chronic GVHD is a different biological story. Instead of a sharp inflammatory strike, it involves a longer disturbance of immune regulation. Donor T cells and B cells (the cells that make antibodies) fail to learn tolerance for the host. Over months, this leads to fibrosis, a process in which normal tissue is gradually replaced by stiff scar-like tissue. That is why chronic GVHD can tighten skin, narrow airways and dry out tear glands in a way acute GVHD does not (NIH consensus, PubMed).

Understanding these mechanisms explains a practical point patients often find confusing: the same donor cells causing harm are also the cells hunting down any remaining cancer, a benefit known as the graft-versus-leukemia effect. Treatment does not aim to silence the graft entirely. It aims to calm the attack on healthy tissue while preserving as much of that surveillance as possible.

Why the 100-day rule for acute vs chronic GVHD no longer decides the diagnosis

For decades, the dividing line was a date. GVHD appearing before day 100 after transplant was called acute; anything after day 100 was called chronic. The rule was simple, and it still appears in many patient leaflets (MedlinePlus).

Transplant medicine outgrew it. Newer techniques, including reduced-intensity conditioning (gentler pre-transplant chemotherapy for older or frailer patients) and donor lymphocyte infusions given months later, meant that classic acute GVHD could show up well after day 100. Meanwhile, some patients developed the sclerotic skin or dry eyes of chronic disease earlier than expected.

The NIH consensus project addressed this directly. Its criteria, first published in 2005 and revised in 2014, state that the diagnosis rests on clinical features, not on the number of days since transplant (NIH consensus, PubMed). A blistering rash and profuse diarrhea at day 150 are still acute GVHD, now labeled “late acute.” Tight, thickened skin at day 80 is chronic GVHD.

Why should a patient care about this classification detail? Because it changes the treatment plan. Late acute GVHD is generally approached with the shorter, more intensive strategy used for early acute disease, and the team watches closely for gut and liver involvement. Chronic GVHD, whenever it appears, triggers the broader organ-by-organ assessment and a longer treatment horizon.

The calendar has not become irrelevant. Timing remains a useful clue and is still used in registry data and research. When you read “acute vs chronic GVHD” in a modern clinic note, though, it reflects what the doctor saw and measured, not the date on the chart. If the label seems at odds with your timeline, it is entirely reasonable to ask the team which features led them there.

Which organs acute GVHD targets, and why those three

Acute GVHD concentrates on three organs: the skin, the liver and the gastrointestinal tract. The skin is affected most often, followed by the gut and then the liver (Cleveland Clinic). These are not random targets. Each is a tissue with a rapid cell turnover and a large surface exposed to the outside world or to the bloodstream, and each is heavily damaged by pre-transplant conditioning, which releases the alarm signals that draw donor T cells in.

In the skin, the earliest sign is typically a red or pink rash, often on the palms, soles, ears, neck and upper trunk. It may itch or feel like sunburn. In more severe cases the rash spreads and can blister or peel. Doctors describe the extent as a percentage of body surface area, and they sometimes take a small skin biopsy to confirm that the pattern under the microscope fits GVHD rather than a drug reaction or infection.

In the gut, acute GVHD causes watery diarrhea, which the team measures by daily volume, along with nausea, loss of appetite and cramping pain. Blood in the stool or symptoms that make eating impossible signal a more advanced stage. Because infections such as cytomegalovirus and Clostridioides difficile can produce a very similar picture, stool tests and often an endoscopic biopsy are used to tell them apart.

In the liver, the attack falls on the small bile ducts, and the first evidence is usually a rising bilirubin level on routine blood tests, sometimes before any yellowing of the skin or eyes is visible. Liver GVHD is harder to biopsy safely and is often diagnosed on the combination of blood results and the presence of GVHD elsewhere.

What patients notice, and what the team measures, are different things. That gap is bridged by the grading system covered next.

How acute GVHD grading works and what the numbers mean

Acute GVHD grading turns a bedside impression into a shared language. Each of the three organs is staged from 0 to 4, and the organ stages are combined into an overall grade from I to IV (Johns Hopkins Medicine). The most widely used modern version is the Mount Sinai Acute GVHD International Consortium, or MAGIC, criteria, which refined an older system from the 1970s.

Skin staging is based on how much of the body surface the rash covers and whether it has blistered. Liver staging follows the bilirubin level in the blood, rising through defined bands. Gut staging uses the daily stool volume in adults, with an additional category for severe abdominal pain, bleeding or intestinal obstruction. Persistent nausea and vomiting with a biopsy showing GVHD counts as stage 1 gut disease even without diarrhea.

The overall grade then follows a set of rules. Grade I means skin involvement only, and mild. Grade II is where treatment decisions usually shift, because it involves more extensive skin disease or the first appearance of gut or liver involvement. Grades III and IV describe progressively severe multi-organ disease, and grade IV includes the most extensive skin damage or organ function that is failing.

Why does this matter to a patient? Grade I acute GVHD may be treated with topical steroid creams alone and watched closely. Grade II or higher generally prompts systemic corticosteroids, which are anti-inflammatory medicines given by mouth or vein that suppress the immune attack across the body (Cleveland Clinic). The grade also predicts risk: higher grades carry a greater chance of complications and are linked with poorer outcomes in registry studies.

Grading is repeated, not done once. Teams re-stage every few days during active disease to see whether treatment is working, and a falling grade is often the first reassuring sign a patient hears.

What is considered chronic GVHD?

Chronic GVHD is defined by a set of characteristic signs rather than by a date. The NIH criteria list “diagnostic” features, which are sufficient on their own to make the diagnosis, and “distinctive” features, which are suggestive but need confirmation by biopsy or another test, and which cannot be explained by infection, medication or another cause (NIH consensus, PubMed).

Diagnostic features include lichen planus-like changes in the mouth or on the skin (flat, purplish or lacy patches), sclerosis (hardening and tightening of the skin or the tissues beneath it), poikiloderma (a mottled mix of thin, discolored skin), narrowing webs in the esophagus, fasciitis (inflammation and stiffening of the connective tissue sheets around muscles), and bronchiolitis obliterans syndrome, a form of scarring in the small airways of the lungs that shows up as breathlessness and a fall in lung function tests.

Distinctive features include loss of skin pigment, new dry eyes with reduced tear production, mouth ulcers and dryness, and nail changes such as ridging or loss. Any one of these, once other causes are excluded, can support the diagnosis when combined with a biopsy or a positive test such as an eye examination showing reduced tears.

What chronic GVHD is not is equally instructive. A red rash and diarrhea alone, however late they occur, are not chronic features. Neither is fatigue by itself, nor a single abnormal liver test. The distinction protects patients from being started on years of immunosuppression for something that may be a drug side effect or an infection.

Once diagnosed, chronic GVHD is scored across eight organ systems, each from 0 to 3, and the results are combined into a global severity of mild, moderate or severe. That global score, more than any single symptom, drives whether a patient receives topical care only or systemic treatment.

Chronic GVHD symptoms across eight organ systems

Where acute GVHD is a three-organ disease, chronic GVHD can involve almost any tissue. The NIH scoring system formally assesses eight sites: skin, mouth, eyes, gastrointestinal tract, liver, lungs, joints and fascia, and the genital tract (NIH consensus, PubMed). Patients rarely have all eight. Many have two or three, and the particular combination shapes daily life as much as the overall severity does.

Skin is the most frequently involved. Early changes may look like eczema or a flat rash; later changes include thickening, tightness and reduced ability to sweat. Mouth involvement brings dryness, sensitivity to spicy or acidic food, and lacy white patches on the inner cheeks. Eye involvement, often described as grittiness or a feeling of sand under the lids, reflects damage to tear glands and can threaten the cornea if untreated.

Lung involvement is the form the transplant team worries about most, because bronchiolitis obliterans syndrome can progress silently before breathlessness is noticed. This is why many centers schedule routine breathing tests during the first years after transplant even in patients who feel well (NHS).

Joint and fascial involvement shows up as stiffness, reduced range of motion or difficulty fully extending the fingers or wrists. Genital involvement, which is under-reported because patients are often not asked, can cause pain, dryness and scarring, and it deserves the same attention as any other organ.

Liver and gut changes in chronic GVHD tend to be quieter than in acute disease: gradual weight loss, difficulty swallowing from esophageal narrowing, or slowly rising liver enzymes. Because these symptoms are broad and overlap with medication effects, infection and deconditioning, they are interpreted by the team as part of a whole picture rather than in isolation. Reporting new changes early, even ones that seem trivial, gives the team the best chance of scoring accurately and acting before scarring sets in.

Acute vs chronic GVHD at a glance

The table below gathers the main contrasts into one place. It is a summary, not a diagnostic tool; only the transplant team can decide which category fits, and overlap syndrome means some patients sit in both columns at once (NIH consensus, PubMed).

Feature	Acute GVHD	Chronic GVHD
Typical onset	Weeks to about three months after transplant; “late acute” can occur after day 100	Usually after the first few months; may follow, overlap with, or arise without prior acute GVHD
Main organs	Skin, gut, liver	Skin, mouth, eyes, gut, liver, lungs, joints and fascia, genital tract
Underlying process	Rapid inflammation driven by activated donor T cells	Disordered immune regulation leading to inflammation and fibrosis (scarring)
Grading system	Organ stages 0–4 combined into overall grade I–IV (MAGIC criteria)	Organ scores 0–3 combined into global mild, moderate or severe (NIH criteria)
First-line treatment	Topical steroids for mild skin-only disease; systemic corticosteroids from grade II	Topical or local therapy for mild disease; systemic corticosteroids for moderate to severe
Usual treatment horizon	Weeks to months	Often years, with gradual tapering
Key monitoring	Daily rash extent, stool volume, bilirubin	Regular lung function tests, eye exams, skin and joint assessment

Two patterns in the table deserve emphasis. First, the treatment starting point is the same for both forms: corticosteroids remain the standard first-line systemic therapy in each (Cleveland Clinic). Second, the horizons diverge sharply. Acute GVHD is treated as a sprint, chronic GVHD as a long walk, and the monitoring that accompanies each is built accordingly.

Who is most at risk of GVHD after bone marrow transplant, and who is usually watched rather than treated

Risk is not evenly spread. GVHD only occurs after an allogeneic transplant; patients who receive their own cells back (an autologous transplant) do not develop it. Among allogeneic recipients, the closeness of the HLA match is the single strongest factor. Cleveland Clinic estimates that GVHD of some form affects roughly half of allogeneic transplant recipients, with the risk rising as the match becomes less complete (Cleveland Clinic).

Other factors that increase risk include an older recipient or donor, a female donor for a male recipient (because prior pregnancies can sensitize the donor’s immune system), the use of peripheral blood stem cells rather than marrow, and higher-intensity conditioning. Having had acute GVHD is the strongest predictor of later chronic GVHD, though chronic disease can appear without any acute phase (Johns Hopkins Medicine).

Prevention starts before transplant. Most patients receive prophylactic immunosuppression, commonly a calcineurin inhibitor (a class of medicine that dampens T cell activation) combined with another agent, or post-transplant cyclophosphamide, a chemotherapy given shortly after infusion to remove the most reactive donor cells. The choice depends on the donor type, the disease being treated and center protocol, and it belongs to the transplant physician.

Not everyone with GVHD is treated systemically, and this surprises many patients. Grade I acute GVHD limited to the skin is often managed with topical steroid creams and close observation. Mild chronic GVHD, meaning one or two organs with low scores and no lung involvement, is frequently handled with local measures: steroid mouth rinses, lubricating eye drops, moisturizers and physiotherapy. The team is, in effect, asking these patients to wait, because systemic immunosuppression carries infection risk and can blunt the graft-versus-leukemia effect (NHS).

Watching is not neglect. It is an active strategy with scheduled reassessment, and the threshold for escalating is agreed in advance.

What is the first-line treatment for chronic GVHD, and how does it differ from acute?

The first-line systemic treatment for both acute and chronic GVHD is the same class of medicine: corticosteroids. These are synthetic versions of the body’s own stress hormone that broadly suppress immune activation and inflammation (Cleveland Clinic). In acute GVHD, they are typically started once disease reaches grade II, often intravenously in hospital for gut or liver involvement. In chronic GVHD, they are usually reserved for moderate or severe global scores, or for any lung involvement, and are more often given by mouth as an outpatient.

The differences lie in what surrounds the steroids. Patients with acute GVHD are usually still on their prophylactic calcineurin inhibitor, which is continued or adjusted. Those with chronic GVHD may have already tapered off prophylaxis and are sometimes restarted on it alongside steroids. Topical and local therapies carry far more weight in chronic disease: steroid creams, mouth rinses, eye drops that protect the tear film, and physiotherapy to keep joints and fascia mobile are treatments in their own right, not afterthoughts (Johns Hopkins Medicine).

Supportive care is a second pillar. Because steroids and the disease itself leave patients vulnerable, most receive preventive antimicrobials against bacteria, fungi and viruses, and are checked for reactivation of viruses such as cytomegalovirus. Nutrition support matters in gut GVHD, and bone protection matters during prolonged steroid exposure.

How steroids are dosed, tapered and combined with other agents is individualized to the organ pattern, the patient’s other conditions and the response seen at each visit. Those decisions rest entirely with the prescribing transplant team, and patients should never adjust or stop these medicines on their own; abrupt changes can trigger flares or adrenal problems.

The honest summary is that first-line therapy has changed little in decades. Where the field has moved is in what happens when steroids do not work.

What happens when steroids are not enough

A meaningful share of patients do not respond fully to corticosteroids, or flare when the dose is reduced. Doctors call this steroid-refractory or steroid-dependent GVHD, and it is one of the most difficult situations in transplant medicine (Johns Hopkins Medicine). The team usually declares refractoriness after a defined period without improvement, or if disease progresses within the first days of treatment for acute GVHD, or over a longer window for chronic disease.

Second-line options fall into several classes, and describing their mechanisms helps patients follow the conversation. JAK inhibitors block enzymes called Janus kinases that transmit inflammatory signals inside immune cells; one drug in this class, ruxolitinib, has been studied in both acute and chronic steroid-refractory GVHD and is used in many centers. Other agents used in chronic GVHD interfere with B cell signaling or with the pathways that drive fibrosis. Antibody therapies can remove or block specific immune cells. Extracorporeal photopheresis, often shortened to ECP, is a procedure in which a portion of the patient’s white blood cells are drawn out, treated with a light-sensitizing agent and ultraviolet light, and returned, which appears to reset some immune responses.

None of these is a guaranteed rescue. Evidence quality varies by agent and by acute versus chronic setting, and the choice depends on which organs are involved, existing infections, kidney and liver function, and what is available and approved locally. Trials continue, and enrolling in one is a legitimate option the team may raise.

Patients should expect a frank discussion about goals at this stage. In acute GVHD, the aim is to halt tissue damage quickly. In chronic GVHD, the aims are broader: reduce symptoms, prevent further scarring, protect the lungs and eyes, and, wherever possible, reach a point where systemic immunosuppression can be tapered. Progress is measured in months, sometimes in the absence of visible improvement in skin that has already scarred.

What the following weeks and months usually look like

For acute GVHD, the early timeline is compressed. After systemic steroids begin, the team re-stages the skin, stool output and liver tests every few days. Improvement, when it comes, is often visible within the first one to two weeks. If the grade is falling, a taper is planned over several weeks to months; if it is not, the conversation turns to second-line options. Hospital stays for gut GVHD can be prolonged because fluid, electrolyte and nutrition needs have to be managed alongside the immune attack (Cleveland Clinic).

Chronic GVHD runs on a different clock. Treatment courses commonly extend over years, with reassessment at each clinic visit using the same eight-organ NIH scoring so that change can be tracked (NIH consensus, PubMed). Lung function tests are repeated at regular intervals, eye examinations are scheduled, and skin and joint mobility are documented. Tapering of systemic immunosuppression begins only when disease is stable or improving, and it proceeds slowly, because flares during taper are common.

Daily life during this period revolves around three practical themes. Infection avoidance comes first: hand hygiene, prompt reporting of fever, keeping up with the re-vaccination schedule the transplant center provides, and taking preventive antimicrobials exactly as prescribed (NHS). Sun protection comes second, since ultraviolet light can trigger or worsen skin GVHD. Movement comes third: gentle stretching and physiotherapy help preserve range of motion in joints threatened by fascial tightening.

Fatigue is nearly universal and rarely resolves quickly. It reflects the disease, the medicines and the sheer duration of illness. Many patients find it useful to track energy alongside symptoms so that the team can see patterns rather than snapshots.

Timelines here are typical ranges drawn from clinical descriptions, not promises. Individual courses vary widely, and the team will tailor follow-up to the organs involved and the response seen.

Why treating GVHD is always a balancing act

Every GVHD treatment decision weighs three competing risks, and understanding this helps patients make sense of choices that can look cautious or contradictory from the outside.

The first risk is tissue damage from the disease itself. Untreated acute gut GVHD can cause life-threatening fluid loss and bleeding; untreated chronic lung GVHD can leave permanent airway scarring. Acting early protects organs.

The second risk is infection. Corticosteroids and every second-line agent suppress immune function at a time when the new immune system is still immature. Infections, rather than GVHD itself, are a leading cause of death in patients with severe GVHD, which is why teams treat with the lowest effective intensity and pair every escalation with preventive antimicrobials and close monitoring (Johns Hopkins Medicine).

The third risk is relapse of the original cancer. The graft-versus-leukemia effect, in which donor cells destroy residual malignant cells, is a major reason allogeneic transplant works for leukemias and lymphomas. Registry analyses have long observed that patients with mild GVHD tend to have lower relapse rates than those with none, a finding that reflects this shared biology (Mayo Clinic). Heavy immunosuppression may weaken that protection.

This is why a transplant physician may choose to observe grade I skin GVHD rather than treat it systemically, may taper steroids more slowly than a patient would like, or may accept a degree of residual chronic GVHD rather than pushing for complete suppression. It is also why the phrase “a little GVHD is good GVHD,” which patients sometimes hear, is half true and half dangerous: the benefit is real for mild disease, but no clinician wants more of it.

Patients who understand this balance tend to have more productive conversations, because they can ask not just “what will you do?” but “which of the three risks are you most worried about for me right now?”

What people often get wrong about acute vs chronic GVHD

Misunderstandings about GVHD are common, partly because older sources are still widely circulated. Several deserve correcting.

The first is that timing alone defines the type. As covered earlier, current NIH criteria classify GVHD by its features, and acute disease appearing after day 100 is still acute (NIH consensus, PubMed). A patient who develops diarrhea and rash at five months should not assume it is chronic, and neither should their treatment plan.

The second is that chronic GVHD is simply acute GVHD that lasted a long time. The two involve different immune processes and different tissues. Chronic GVHD can develop in people who never had acute disease at all, and acute GVHD can resolve completely without ever becoming chronic (Johns Hopkins Medicine).

The third is that GVHD means the transplant has failed. In fact, GVHD is evidence that the donor immune system has engrafted and is active. It is a complication, sometimes a serious one, but not a failure, and it can coexist with excellent control of the underlying cancer.

The fourth is that chronic GVHD is inevitably lifelong. Many patients do reach a point where systemic immunosuppression can be stopped and symptoms are minimal, although scarring that has already formed, particularly in skin or lungs, may not reverse. Others live with ongoing low-level disease. The trajectory is individual, and the honest answer to “will it go away?” is that it often becomes controlled and sometimes becomes inactive, over a period measured in years.

The fifth is that supplements, special diets or alternative therapies can treat GVHD. No dietary or herbal product has been shown to control GVHD, and some can interact with immunosuppressants or carry infection risk. Nutrition support is a genuine part of care, but it is delivered through the transplant dietitian, not the health-food aisle.

Correcting these beliefs early tends to reduce both false alarm and false reassurance.

Questions to ask your care team

A GVHD diagnosis usually arrives during an already exhausting period, and it is easy to leave clinic with more confusion than clarity. Bringing a short written list helps. The questions below are drawn from what patients most often wish they had asked, and each is phrased so the answer belongs to your own team.

• Is this acute, chronic or overlap GVHD, and which specific features led you to that classification?
• Which organs are involved, what stage or score has each been given, and what is my overall grade or global severity?
• Are you recommending topical or local treatment only, or systemic treatment, and what would make you change that plan?
• What signs of improvement or worsening should I expect to see first, and over roughly what timeframe?
• Which infections am I most at risk of on this treatment, what preventive medicines am I taking, and what fever threshold should prompt a call?
• How will my lungs and eyes be monitored, and how often, even if I have no symptoms there?
• How does this treatment affect the graft-versus-leukemia effect, and how will you monitor my original disease?
• If the first-line treatment does not work, what are the likely next steps, and are there clinical trials I could be considered for?
• Who do I contact after hours, and what information should I have ready when I call?
• Are there physiotherapy, dental, ophthalmology or gynecology referrals that should be arranged now rather than later?

Two further questions concern life beyond the clinic. Ask what a realistic return to work, study or caregiving might look like given your organ involvement, and ask what support exists for the fatigue and emotional strain that accompany long treatment. Transplant programs typically have social workers, psychologists and patient support coordinators, and their input is part of standard care, not an extra (Mayo Clinic).

Write down the answers, or ask permission to record the conversation. Grading numbers and medication names are hard to retain from memory.

When to call your doctor

After an allogeneic transplant, the threshold for calling the team is deliberately low. Transplant programs give patients a direct line for exactly this reason, and no call about a new symptom is considered a nuisance (NHS). Certain signs, however, should prompt an immediate call or, if the team cannot be reached, emergency care.

Fever is the first. A temperature of 38 °C (100.4 °F) or higher, or chills and shaking even without a measured fever, can signal a serious infection in someone on immunosuppression and needs same-day assessment. Do not take medicine to bring the temperature down before calling, as this can mask the picture.

New or spreading rash, especially if it blisters, peels or covers a large area, may indicate acute GVHD or a drug reaction and should be reported the same day. Watery diarrhea that is frequent or large in volume, blood in the stool, severe abdominal pain, or an inability to keep fluids down are urgent, because gut GVHD and its complications can cause rapid dehydration. Yellowing of the skin or eyes, dark urine or pale stools point to liver involvement.

For patients with or at risk of chronic GVHD, new or worsening breathlessness, a persistent dry cough, or a drop in exercise tolerance are red flags for lung involvement and should never wait for the next scheduled visit. Sudden eye pain, marked redness or a change in vision also warrant a prompt call, because corneal damage can progress quickly.

Other reasons to contact the team promptly include confusion or unusual drowsiness, difficulty swallowing that is new or worsening, rapid unexplained weight loss, painful or stiff joints that limit movement, and any vaginal or penile pain or bleeding. If you are unsure whether something matters, call anyway. The team would far rather hear about a symptom that turns out to be minor than learn about a serious one late.

Frequently asked questions

What are the two main types of GVHD?

The two main types are acute and chronic graft-versus-host disease. Acute GVHD typically appears within the first weeks to months after an allogeneic transplant and involves the skin, gut and liver. Chronic GVHD usually develops later, behaves more like an autoimmune condition, and can affect the mouth, eyes, lungs, joints and other organs. An overlap syndrome, with features of both, is also recognized in the NIH consensus criteria.

What is considered chronic GVHD?

Chronic GVHD is diagnosed by characteristic features rather than by timing. The NIH criteria list diagnostic signs such as lichen planus-like changes, skin sclerosis, poikiloderma, esophageal webs, fasciitis and bronchiolitis obliterans syndrome, plus distinctive signs like new dry eyes or nail changes that need confirmation by biopsy or testing. Other causes such as infection or medication must be excluded before the label is applied.

Does chronic GVHD ever go away?

Chronic GVHD often becomes controlled and sometimes becomes inactive, but the trajectory is individual and usually measured in years. Many patients eventually taper off systemic immunosuppression with minimal symptoms. Scarring that has already formed in skin or lungs may not reverse, and some people live with ongoing low-level disease. Your transplant team can give you a more specific picture based on the organs involved and your response to treatment.

What is the first-line treatment for chronic GVHD?

Systemic corticosteroids are the standard first-line treatment for moderate to severe chronic GVHD, often alongside a calcineurin inhibitor. Mild chronic disease is frequently managed with local measures such as steroid mouth rinses, lubricating eye drops, skin creams and physiotherapy. How these are used, and when systemic treatment starts or tapers, is decided by the prescribing transplant physician based on organ scores and overall severity.

How does acute GVHD grading work?

Each of the three target organs is staged from 0 to 4. Skin staging follows the percentage of body surface covered by rash, liver staging follows bilirubin levels, and gut staging follows daily stool volume plus pain or bleeding. The organ stages are then combined into an overall grade from I to IV using the MAGIC criteria. Grade II or higher generally prompts systemic corticosteroid treatment.

Can you get chronic GVHD without having acute GVHD first?

Yes. Although prior acute GVHD is the strongest single predictor of chronic GVHD, chronic disease can arise in patients who never had an acute phase. This is one reason clinicians think of the two as biologically distinct processes rather than as one disease at two stages. It is also why follow-up monitoring for chronic features continues even in patients whose early course was uneventful.

How common is GVHD after bone marrow transplant?

GVHD only occurs after an allogeneic transplant, where cells come from a donor. Cleveland Clinic estimates that some form of GVHD affects roughly half of allogeneic recipients, with risk rising when the HLA match is less complete, when donors are unrelated or older, and when peripheral blood rather than marrow is used. Patients receiving their own cells back in an autologous transplant do not develop GVHD.

What is late acute GVHD?

Late acute GVHD is acute-type disease, with classic features such as rash, diarrhea or rising bilirubin, that appears after the traditional 100-day cutoff. It is more often seen after reduced-intensity conditioning or donor lymphocyte infusions. Under current NIH criteria it is classified and treated as acute GVHD, not chronic, because the clinical picture rather than the calendar determines the diagnosis and the treatment approach.

Why do doctors sometimes not treat mild GVHD?

Mild GVHD, such as grade I skin-only acute disease or mild chronic disease without lung involvement, is often watched or treated locally because systemic immunosuppression carries infection risk and can weaken the graft-versus-leukemia effect that helps prevent cancer relapse. Observation is an active plan with scheduled reassessment and an agreed threshold for escalating, not a decision to do nothing.

What is overlap syndrome in GVHD?

Overlap syndrome describes a patient who has features of both acute and chronic GVHD at the same time, for example a classic acute rash and diarrhea together with sclerotic skin or dry eyes. It is recognized in the NIH consensus criteria as a subtype of chronic GVHD. Identifying overlap matters because it signals that both processes are active, which influences treatment intensity and duration.

References

• Graft-versus-host disease, MedlinePlus Medical Encyclopedia
• Stem cell and bone marrow transplants: Risks, NHS
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: 2014 Diagnosis and Staging Working Group Report (PubMed)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.